[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616975":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":25,"locations":35,"responsibleParty":54,"collaborators":58,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Mansoura University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intra-Lesional Immunotherapy","EXPERIMENTAL","All participants with recalcitrant tinea cruris and\u002For tinea corporis will receive intra-lesional immunotherapy. There is no comparator or placebo group. Male and female participants are included in the same arm and will be analyzed as subgroups.Intra-Lesional Immunotherapy",[13],"Biological: Intra-Lesional MMR Immunotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Intra-Lesional MMR Immunotherapy","Participants will receive intra-lesional immunotherapy using the measles-mumps-rubella (MMR) vaccine. The vaccine will be injected into the active borders of affected lesions every 2 weeks for a total duration of 6 weeks. Clinical assessment of lesion extent and symptoms, particularly pruritus, will be performed at baseline and at each visit. If partial clinical improvement is observed after the initial 6 weeks but complete resolution is not achieved, the treatment course may be extended for an additional 6 weeks, with a maximum of six intra-lesional injection sessions.",[9],[21,22,23],"MMR Vaccine","Measles-Mumps-Rubella Vaccine","Priorix®",null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Abeer Mohamed Elkholy, MD degree of Dermatology","CONTACT","+201006210646","abeerkholy@hotmail.com",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"Nora Mohamed Abdelrazik, MD degree of Dermatology","+201060291029","noraeldarawany@gmail.com",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Al Mansurah","Dakahlia Governorate","35511","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.38069,31.03637,{"lat":47,"lon":46},[50],{"name":51,"role":28,"phone":52,"phoneExt":24,"email":53},"Ahmed Ibrahim Ali, Master degree of Dermatology","+201011442104","Ahmed.abdelhadi@med.suezuni.edu.eg",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Abeer Mohamed Abdelaziz Elkholy","Professor of Dermatology, Faculty of Medicine, Mansoura University",[59],{"name":5,"class":6},"100616975","a-pilot-study-to-evaluate-the-therapeutic-efficacy-of-intra-lesional-immunotherapy-in-patients-aged-10-60-years-with-recalcitrant-tinea-cruris-and-corporis-100616975",false,"NCT07312604","A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis","Evaluating the Therapeutic Efficacy of Intra-lesional Immunotherapy Against Recalcitrant Tinea Cruris & Corporis: a Pilot Study","IL-ImmuneRTC","Inclusion Criteria:\n\n* Age between 10 - 60 years.\n* Evidence of recalcitrant tinea e.g. (rapid progression \\& large areas affected of the body, affection of more than one family members especially females \\& children, rapid relapse after treatment, suspicion of resistant T. indotineae strain by history of traveling abroad \\& contact with Indians or contact with a case coming from travel \\& with contact to Indians.\n* Patients failed at least 2 courses of systemic antifungal therapy in the last 3 months.\n* Safe contraception during the study (for females in the childbearing period).\n\nExclusion Criteria:\n\n* Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception.\n* Age \\\u003C10 years or \\> 60 years.\n* Immunocompromised patients e.g. (uncontrolled DM or HIV patients).\n* Naïve patients without previous systemic antifungal treatment.\n* Unreliable patients.","ALL","10 Years","60 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"NA","This pilot study will test intra-lesional immunotherapy (MMR vaccine) injections as a treatment for recalcitrant tinea cruris and corporis in patients aged 10-60 years who have not improved with standard antifungal treatments.\n\n\\*Eligibility: Participants must have recalcitrant tinea, defined as:\n\n* Rapid progression or large areas of skin affected,\n* Infection in multiple family members, especially females and children\n* Rapid relapse after prior treatment\n* Suspected resistant T. indotineae (based on travel history or contact with affected individuals from high-prevalence regions)\n* Failure of at least 2 courses of systemic antifungal therapy in the past 3 months\n\nTreatment: Patients will receive intra-lesional MMR vaccine injections into the active borders of affected lesions every 2 weeks for up to 6 weeks. If partial improvement occurs but complete clearance is not achieved, the course may be repeated for another 6 weeks. Pulse itraconazole will be given during the first 2 weeks.\n\nMonitoring: At each study visit, clinicians will assess the extent of affected skin and monitor symptoms particularly itching. Safety will be closely observed, including injection-site reactions, fever, initial flare of lesions, and any rare serious allergic reactions.\n\nGoal: To evaluate the safety and effectiveness of intra-lesional MMR immunotherapy for patients with tinea that has been difficult to treat.",[79,80],"Tinea Corporis","Tinea Cruris",[80,79,82,9,83,84],"Recalcitrant Dermatophytosis","Pilot Clinical Study","Dermatophyte Treatment","2025-12-17",{"date":87,"type":88},"2025-12-31","ACTUAL",{"date":90,"type":88},"2025-12-09",{"date":92,"type":73},"2026-03-09",{"name":56,"class":6},1]